Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.42 |
| ▸ | PLG | P00747 | 1/20 | 0.39 |
| ▸ | PLAT | P00750 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8899930 | 1.00 | NCF1 (0.42) | NCF1PLGPLATLMNASPHK1 | |
| SCHEMBL16293253 | 0.85 | NCF1 (0.34) | NCF1PLGPLATLMNA | |
| Decarboxylated Derivative SCHEMBL21357939 | 0.83 | CYP2D6 (0.41) | NCF1LMNA | |
| Trifluoroacetic Acid SCHEMBL8906248 | 0.81 | PLG (0.44) | NCF1PLGPLATLMNA | |
| SCHEMBL6662255 | 0.80 | SIGMAR1 (0.32) | — | |
| SCHEMBL152273 | 0.78 | TDP1 (0.32) | SPHK1 | |
| SCHEMBL23299298 | 0.77 | NCF1 (0.37) | NCF1PLGPLATLMNA | |
| SCHEMBL1703765 | 0.76 | PLG (0.55) | NCF1PLGPLATLMNA | |
| SCHEMBL432248 | 0.76 | PLG (0.55) | NCF1PLGPLATLMNA | |
| SCHEMBL48375 | 0.76 | PLG (0.55) | NCF1PLGPLATLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9802919-B1 | Compounds | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-10-31 | — | — | US | disclosed |
| EP-2753329-B1 | 1,5-NAPHTHYRIDINE DERIVATIVES AS MELK INHIBITORS | ONCOTHERAPY SCIENCE INC (JP) | 2017-08-09 | — | — | EP | disclosed |
| US-9345709-B2 | 1,5-naphthyridine derivatives and MELK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2016-05-24 | — | — | US | disclosed |
| EP-2597955-B1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE INC (JP) | 2016-01-20 | — | — | EP | disclosed |
| US-20150328225-A1 | 1,5-NAPHTHYRIDINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2015-11-19 | — | — | US | disclosed |
| US-9120749-B2 | Quinoline derivatives and MELK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2015-09-01 | — | — | US | disclosed |
| US-9067937-B2 | 1,5-naphthyridine derivatives and MELK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2015-06-30 | — | — | US | disclosed |
| US-20150005302-A1 | 1,5-NAPHTHYRIDINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2015-01-01 | — | — | US | disclosed |
| US-20130217671-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2013-08-22 | — | — | US | disclosed |
| WO-2013067423-A1 | PAK INHIBITORS FOR THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | AFRAXIS, INC. (US) | 2013-05-10 | — | — | WO | disclosed |
| WO-2011079105-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | WO | disclosed |
| EP-1022273-B1 | Pigment composition containing a pigment dispersing agent | TOYO INK MFG CO (JP) | 2004-07-14 | — | — | EP | disclosed |
| US-6123763-A | PROVIDES AN INK OR A COATING COMPOSITIONFREEDOM OF AGGREGATION, NON-CRYSTALLIZABILITY AND FLUIDITY, | TOYO INK MFG. CO., LTD. (JP) | 2000-09-26 | — | — | US | disclosed |
| EP-1022273-A1 | Pigment dispersing agent and pigment composition containing the same | TOYO INK MANUFACTURING CO., LTD. (JP) | 2000-07-26 | — | — | EP | disclosed |
| WO-1997020823-A2 | 2-AMINO QUINAZOLINE DERIVATIVES AS NPY RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 1997-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150328225-A1 | 1,5-NAPHTHYRIDINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | MELK, NEK1, NEK5 | NCF1 303/4885PLG 2450/4885PLAT 1880/4885 |
| US-20150005302-A1 | 1,5-NAPHTHYRIDINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | MELK, NEK1, NEK5 | NCF1 303/4885PLG 2450/4885PLAT 1880/4885 |
| US-20130217671-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | MELK, NADK, NEK1 | NCF1 1292/4885PLG 4658/4885PLAT 4567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.